OUP user menu

Journal of Crohn's and Colitis: 9 (5)

Editor-in-Chief

Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium

3.562
4.023

Published on behalf of

Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31

Casper Steenholdt , Magid Al-Khalaf , Mark A. Ainsworth , Jørn Brynskov
DOI: http://dx.doi.org/10.1016/j.crohns.2011.10.002 358-361 First published online: 1 April 2012

Abstract

A 26 year old woman with ulcerative colitis was treated with regular infliximab (IFX) infusions until gestation week 31, and gave birth to a healthy child at gestation week 37. Maternal IFX trough level was relatively high during the course of pregnancy. In the infant, therapeutic level of IFX was detectable at week 16 after birth, but not at reassessment at week 28. Anti-IFX antibodies were consistently below the detection limit in the patient and in the child. This case illustrates that IFX is transferred through the placenta to the embryo, and may result in therapeutic drug levels in the newborn child despite IFX discontinuation in third trimester 6 weeks prior to delivery. The half life of IFX appeared markedly longer in infants as compared to adults. The safety of IFX beyond the first trimester is unknown, and this case highlights the need for further investigations of maternal transfer of IFX as well as the risks associated with IFX administrations in the second and third trimester.

Keywords
  • Inflammatory bowel disease
  • Ulcerative colitis
  • Infliximab
  • Anti-infliximab antibody
  • TNF
  • Pregnancy
  • Abbreviations:
    Ab
    antibodies
    ASA
    aminosalicylic acid
    CRP
    C-reactive protein
    IBD
    inflammatory bowel disease
    IFX
    infliximab
    RIA
    radioimmunoassay
  • View Full Text

    Log in through your institution